2023 World Conference on Lung Cancer (Posters)-EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT)

EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT) - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to determine the predictive factors for toxicity and response to immunotherapy in patients with metastatic non-small cell lung cancer. The authors conducted a single-center, prospective, observational study called IMMUNOPREDICT. They evaluated the proportion of patients who experienced changes in biological markers of immunity during immunotherapy.<br /><br />The study included 31 patients between January 2021 and January 2022. The median follow-up time was 11.2 months. The overall survival rate at 6 months was 87%, while the overall survival rate at September 2022 was 70.9%. The progression-free survival rate at 6 months was 48.4%.<br /><br />The authors did not observe a statistical correlation between the presence of pre-existing autoantibodies or those arising during immunotherapy and the development of secondary autoimmune effects. They also found no significant difference in overall survival or progression-free survival between patients with or without autoantibodies.<br /><br />Furthermore, there was no significant difference in the occurrence of autoimmune effects in terms of progression-free survival or overall survival. Lymphopenia, complement depletion, and the general condition of the patient did not significantly influence efficacy or the development of autoimmune effects.<br /><br />In conclusion, the prediction of toxicity and response to immunotherapy in metastatic non-small cell lung cancer appears to be complex and not solely dependent on lymphopenia, complement depletion, or autoantibodies. Future studies should consider multiple factors to identify predictive factors for response and toxicity.<br /><br />Keywords: immunotherapy, prediction, toxicity.

Asset Subtitle

Jessica Nguyen

Meta Tag

Speaker Jessica Nguyen

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

immunotherapy

predictive factors

toxicity

response

metastatic non-small cell lung cancer

IMMUNOPREDICT

biological markers

prospective observational study

autoantibodies

overall survival rate